Baillie Gifford & CO Vertex Pharmaceuticals Inc Transaction History

Baillie Gifford & CO

$131 Billion
Q3 2024

A detailed history of Baillie Gifford & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baillie Gifford & CO holds 140,580 shares of VRTX stock, worth $57.6 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

140,580

Previous 167,616 16.13%

Holding current value

$57.6 Million

Previous $78.6 Million 16.78%

% of portfolio

0.05%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$460.0 - $505.78 $12.4 Million - $13.7 Million	-27,036 Reduced 16.13%	140,580 $65.4 Million
Q2 2024 Jul 25, 2024	BUY	$392.81 - $485.53 $65.8 Million - $81.4 Million	167,616 New	167,616 $78.6 Million
Q2 2019 Aug 08, 2019	SELL	$164.61 - $190.37 $69.9 Million - $80.9 Million	-424,845 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$163.73 - $194.7 $49.5 Million - $58.9 Million	-302,317 Reduced 41.57%	424,845 $0
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $20.1 Million - $25.5 Million	132,435 Added 22.27%	727,162 $120 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $2.73 Million - $3.14 Million	16,288 Added 2.82%	594,727 $115 Million
Q2 2018 Jul 17, 2018	BUY	$145.72 - $169.96 $4.63 Million - $5.4 Million	31,744 Added 5.81%	578,439 $98.3 Million
Q1 2018 May 10, 2018	BUY	$151.6 - $177.13 $7.32 Million - $8.56 Million	48,317 Added 9.69%	546,695 $89.1 Million
Q4 2017 Feb 13, 2018	BUY	$137.28 - $155.55 $898,772 - $1.02 Million	6,547 Added 1.33%	498,378 $74.7 Million
Q3 2017 Oct 20, 2017	BUY	$148.13 - $162.24 $923,442 - $1.01 Million	6,234 Added 1.28%	491,831 $74.8 Million
Q2 2017 Aug 10, 2017	BUY	N/A	485,597	485,597 $62.6 Million

Others Institutions Holding VRTX

# of Institutions

1,725

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Vertex Pharmaceuticals Inc Transaction History